ArticleScientific reports2025
Time-resolved fluoroimmunoassay improves sensitivity in the diagnosis of primary membranous nephropathy with low phospholipase A2 receptor antibody titer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To evaluate the diagnostic utility of time-resolved fluoroimmunoassay (TRFIA) for detecting serum anti-Phospholipase A2 Receptor (PLA2R) antibodies, specifically the IgG (PLA2R-IgG) and IgG4 subclass (PLA2R-IgG4). A total of 175 patients with serum anti-PLA2R antibody range from 2 to 20 RU/ml, between January 2018 and December 2024, were retrospectively analyzed. 121 serum specimen were tested by TRFIA and ELISA. According to renal biopsy, 52% (91/175) patients were diagnosed with primary membranous nephropathy (PMN). Notably, TRFIA exhibited higher sensitivity and specificity in identifying patients with PMN. Based on the manufacturer's recommended cutoff values, TRFIA demonstrated a higher sensitivity of 14.3% for PLA2R-IgG and 34.1% for PLA2R-IgG4 compared to ELISA (0%). Receiver operating characteristic analysis showed that TRFIA achieved an area under the curve (AUC) of 0.829 for PLA2R-IgG and 0.814 for PLA2R-IgG4.The optimal anti-PLA2R antibody cutoff values for diagnosing PMN were 0.44 RU/ml (PLA2R-IgG-TRFIA) and 25.07 ng/ml (PLA2R-IgG4-TRFIA) with a sensitivity/specificity of 83.3%/82.4% for PLA2R-IgG-TRFIA, and 83.3% /76.9% for PLA2R-IgG4-TRFIA, both of which were higher than those of ELISA (cutoff:2.84 RU/ml; sensitivity/specificity: 50%/88%). In conclusion, TRFIA demonstrates enhanced sensitivity and specificity in detecting anti-PLA2R antibodies, which may facilitate more accurate diagnosis of PMN and minimize the need for invasive renal biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.